{"id":"NCT02512042","sponsor":"Actavis Inc.","briefTitle":"Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes","officialTitle":"A Multicentre, Double Blind, Active Controlled, Parallel Group, Two Arm, Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% Ophthalmic Suspension of Alcon Laboratories, Inc., In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2016-04","completion":"2016-05","firstPosted":"2015-07-30","resultsPosted":"2020-03-02","lastUpdate":"2020-03-02"},"enrollment":973,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"OTHER"},"conditions":["Glaucoma"],"interventions":[{"type":"DRUG","name":"Test-Brinzolamide 1% Ophthalmic suspension","otherNames":[]},{"type":"DRUG","name":"Reference-Brinzolamide 1% Ophthalmic suspension","otherNames":[]}],"arms":[{"label":"Brinzolamide 1% Ophthalmic suspension","type":"EXPERIMENTAL"},{"label":"Azopt® 1% Ophthalmic suspension","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% ophthalmic suspension of Alcon Laboratories, Inc. in the treatment of chronic open angle glaucoma or ocular hypertension in both eyes.","primaryOutcome":{"measure":"Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time Points","timeFrame":"Day 14 and 42 at 8AM and 10AM","effectByArm":[{"arm":"Generic Brinzolamide Ophthalmic Suspension USP 1%","deltaMin":19.35,"sd":2.86},{"arm":"Azopt® (Brinzolomide Ophthalmic Suspension USP 1%)","deltaMin":19.75,"sd":2.874}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":489},"commonTop":["Eye irritation","Vision blurred","Headache","Eye pain","Ocular hyperaemia"]}}